← EU FEED

Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PDTM 2026 Conference

AI BRIEFING

  • Galimedix Therapeutics to present promising pre-clinical data with next generation oral amyloid beta aggregation modulator at AD/PDTM 2026 Conference
  • Kensington, MD, USA and Munich/Martinsried, Germany
  • GLOBE NEWSWIRE
ADVERTISEMENT
READ ORIGINAL ARTICLE